167 related articles for article (PubMed ID: 32660355)
1. Expression of UDP Glucuronosyltransferases
Shafiee-Kermani F; Carney ST; Jima D; Utin UC; Farrar LB; Oputa MO; Hines MR; Kinyamu HK; Trotter KW; Archer TK; Hoyo C; Koller BH; Freedland SJ; Grant DJ
Epigenetics; 2021 Mar; 16(3):289-299. PubMed ID: 32660355
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
Wijayakumara DD; Hu DG; Meech R; McKinnon RA; Mackenzie PI
J Pharmacol Exp Ther; 2015 Sep; 354(3):417-25. PubMed ID: 26163549
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.
Pâquet S; Fazli L; Grosse L; Verreault M; Têtu B; Rennie PS; Bélanger A; Barbier O
J Clin Endocrinol Metab; 2012 Mar; 97(3):E428-32. PubMed ID: 22170718
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
Margaillan G; Lévesque É; Guillemette C
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):85-93. PubMed ID: 26385605
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.
Hu DG; Mackenzie PI
Drug Metab Dispos; 2010 Dec; 38(12):2105-9. PubMed ID: 20736324
[TBL] [Abstract][Full Text] [Related]
6. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
7. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.
Chouinard S; Barbier O; Bélanger A
J Biol Chem; 2007 Nov; 282(46):33466-33474. PubMed ID: 17848572
[TBL] [Abstract][Full Text] [Related]
8. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues.
Bélanger A; Hum DW; Beaulieu M; Lévesque E; Guillemette C; Tchernof A; Bélanger G; Turgeon D; Dubois S
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):301-10. PubMed ID: 9699884
[TBL] [Abstract][Full Text] [Related]
9. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
11. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
[TBL] [Abstract][Full Text] [Related]
12. UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
Grant DJ; Chen Z; Howard LE; Wiggins E; De Hoedt A; Vidal AC; Carney ST; Squires J; Magyar CE; Huang J; Freedland SJ
BMC Cancer; 2017 Jul; 17(1):463. PubMed ID: 28673330
[TBL] [Abstract][Full Text] [Related]
13. Intergenic Splicing between Four Adjacent
Hu DG; Hulin JA; Wijayakumara DD; McKinnon RA; Mackenzie PI; Meech R
Mol Pharmacol; 2018 Sep; 94(3):938-952. PubMed ID: 29959221
[TBL] [Abstract][Full Text] [Related]
14. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
15. Regulation of UDP-Glucuronosyltransferase 2B15 by miR-331-5p in Prostate Cancer Cells Involves Canonical and Noncanonical Target Sites.
Wijayakumara DD; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2018 Apr; 365(1):48-59. PubMed ID: 29367276
[No Abstract] [Full Text] [Related]
16. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.
Kaeding J; Bouchaert E; Bélanger J; Caron P; Chouinard S; Verreault M; Larouche O; Pelletier G; Staels B; Bélanger A; Barbier O
Biochem J; 2008 Mar; 410(2):245-53. PubMed ID: 17988216
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells.
Guillemette C; Lévesque E; Beaulieu M; Turgeon D; Hum DW; Bélanger A
Endocrinology; 1997 Jul; 138(7):2998-3005. PubMed ID: 9202245
[TBL] [Abstract][Full Text] [Related]
18. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
Bao BY; Chuang BF; Wang Q; Sartor O; Balk SP; Brown M; Kantoff PW; Lee GS
Prostate; 2008 Jun; 68(8):839-48. PubMed ID: 18302198
[TBL] [Abstract][Full Text] [Related]
20. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.
Lévesque E; Beaulieu M; Guillemette C; Hum DW; Bélanger A
Endocrinology; 1998 May; 139(5):2375-81. PubMed ID: 9564848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
